Robert E. Gagnon - 18 Mar 2026 Form 3 Insider Report for PURPLE BIOTECH LTD. (PPBT)

Role: Director
Signature: /s/ Robert Gagnon
Issuer symbol: PPBT
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 18:06:33 UTC
Previous filing: 26 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gagnon Robert E.	Director	14 WHITRIDGE RD, NATICK	/s/ Robert Gagnon	18 Mar 2026	0001504983

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PPBT	Ordinary Shares						3,062,500	18 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PPBT	Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	112,500		Direct	F2
holding	PPBT	Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	300,000		Direct	F3
holding	PPBT	Stock Option (Right to Buy)							18 Mar 2026	Ordinary Shares	2,650,000		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
F2	Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 56 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.146765625 per Ordinary Share and the option expires on December 29, 2026.
F3	Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24,2026.The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.
F4	Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2029.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.